Consumer Cyclical
Baijin Life Science Holdings Limited(MNNGF)
Live Price
Offline$0.075
+0.00% today
1Y Change
-6.25%
Window
Jun 25, 2025 β Jun 15, 2026
- Market Cap
- $410.00M
- Revenue Growth
- +152.5%
- EPS Growth
- +95.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars Β· Jun 25, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Baijin Life Science Holdings Limited (MNNGF) is a Consumer Cyclical stock with a market cap of $410.00M and listed on OTC. The stock last traded around $0.08 and down 6.2% across the available one-year price window (Jun 25, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of +152.5%, EPS growth of +95.7%, a dividend yield of 0.0%. What stands out right now is revenue +152.5%, EPS +95.7%, free cash flow -396.9% with operating margin -12.0% and ROIC 45.2%. Valuation already assumes a fairly strong business story at P/E 50.6 and price/sales 3.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MNNGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Cyclical peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+152.5% vs +7.5% peer median
Operating Margin
Below sector median
-12.0% vs +8.4% peer median
P/E
Above sector median
50.6 vs 18.1 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2024 was reported on Nov 29, 2024, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +152.5% and EPS at +95.7%, with operating margin around -12.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2024 Nov 29, 2024 | β | +0.0% | +0.0% | +0.0% |
2024 Jul 31, 2024 | β | +0.0% | +0.0% | +0.0% |
2024 Feb 8, 2024 | β | +0.0% | +0.0% | +0.0% |
Benchmark Edge
MNNGF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MNNGF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MNNGF Max Drawdown
-43.75%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MNNGF and SPY.
Company Overview
Baijin Life Science Holdings Limited
Other OTC
Baijin Life Science Holdings Limited, an investment holding company, engages in the purchase, process, design, production, assembly, trade, and wholesale distribution of pearls and jewelry products. It operates in two segments, Sales of Pearls and Jewellery Products, and Strategic Investment and Financial Services. The company is also involved in the real estate financial assets investment business. It has operations in Hong Kong, the United Kingdom, the United States, Japan, Europe, and the People's Republic of China. The company was formerly known as Man Sang Jewellery Holdings Limited and changed its name to Affluent Partners Holdings Limited in February 2017. Affluent Partners Holdings Limited was incorporated in 2014 and is based in Central, Hong Kong.
- Leadership
- Sze Ming Cheung
- IPO Date
- Apr 10, 2015
- Employees
- 84
- Street Address
- Wings Building
- Mailing
- Central
- Region
- Central, HK
- Reporting Currency
- USD
- Investor Line
- 852 3611 2188
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 50.6
- EV/EBITDA
- 41.8
- Price/Sales
- 3.4
- Price/Book
- 2.9
Growth
- Revenue
- +152.5%
- EPS
- +95.7%
- Free Cash Flow
- -396.9%
Profitability
- Gross Margin
- 28.1%
- Operating Margin
- -12.0%
- Net Margin
- 6.7%
- ROE
- 5.8%
- ROIC
- 45.2%
Balance Sheet
- Debt/Equity
- 0.61
- Current Ratio
- 4.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.